<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[fda and gel Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/fda+and+gel.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to fda and gel]]></description>
	<s:counts start="0" returned="4" found="4" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Barrier Therapeutics Announces FDA Acceptance of Its New Drug Application for Sebazole(TM) Topical Gel]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200512/ai_n15917313]]></link>
		<description><![CDATA[Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that the U.S. Food and Drug Administration FDA has accepted for filing the Company's New Drug Application NDA for SebazoleTM (ketoconazole USP 2%) topical gel for the treatment of seborrheic dermatitis....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 09 Dec 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/barrier.html"><![CDATA[barrier]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/gel.html"><![CDATA[gel]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[INAMED Receives FDA Approvable Letter for Its Responsive Silicone Gel Filled Breast Implants]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_Sept_21/ai_n15402181]]></link>
		<description><![CDATA[SANTA BARBARA, Calif. -- INAMED Corporation (Nasdaq:IMDC), a global healthcare company, today announced that it has received an "approvable letter" from the Food and Drug Administration FDA for its responsive silicone gel filled breast implants. The approvable letter stipulates a number of conditions that INAMED must comply with in order...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 21 Sep 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/breast.html"><![CDATA[breast]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/gel.html"><![CDATA[gel]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[SOLVAY Pharmaceuticals.(receives approval for AndroGel 1 percent)(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200003/ai_n13211896]]></link>
		<description><![CDATA[SOLVAY Pharmaceuticals' Unimed has received FDA approval for  its AndroGel 1 percent (testosterone gel, C-III). The approval marks the  first-ever testosterone replacement gel to be approved by FDA for  replacement therapy in men for ...    SOLVAY Pharmaceuticals' Unimed has received FDA approval for ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 06 Mar 2000 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/gel.html"><![CDATA[gel]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Columbia Laboratories Submits U.S. New Drug Application for Crinone, Its Locally-Delivered Natural Progesterone Gel]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1996_July_24/ai_18516207]]></link>
		<description><![CDATA[MIAMI--HealthWire--July 24, 1996--Columbia Laboratories, Inc.  (ASE: COB) today announced the submission of a New Drug Application NDA to the U.S.  Food and Drug Administration FDA for clearance to market CrinoneR, its locally-delivered natural progesterone gel, as a hormonal therapy for patients with secondary amenorrhea loss of menstrual period....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 24 Jul 1996 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/gel.html"><![CDATA[gel]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
